Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

HOPKINTON, Mass., October 18, 2007 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced that Dr. Frank Bobe, Executive Vice President and Chief Business Officer of Alseres Pharmaceuticals, Inc., will be presenting at Windhover Information's 2nd Annual Therapeutic Area Partnerships in Philadelphia, PA October 24-26, 2007. Dr. Bobe will be presenting an overview on Alseres Regenerative Therapeutics program. Cethrin(R), the Company's lead regenerative therapeutic for acute spinal cord injury, was named one of the "Top 10 Licensable Neuroscience Projects" by Windhover.

Windhover Information's 2nd Annual Therapeutic Area Partnerships is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic and Neuroscience. Decision-makers (business development and R & D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. For more information on the conference and speaking companies please go to http://www.tapartnerships.com .

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.


    Contact:  Sharon Correia

              Director, Corporate Communications

              

              508-497-2360 ext. 224

scorreia@alseres.com

CONTACT: Sharon Correia, Director, Corporate Communications of AlseresPharmaceuticals, Inc., +1-508-497-2360, ext. 224, scorreia@alseres.com

Web site: http://www.alseres.com/http://www.tapartnerships.com/

Ticker Symbol: (NASDAQ-NMS:ALSE)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007

View comments

Hide
(web1)